Financial Results
Arrow Greentech Publishes Q2 FY27 Results
Arrow Greentech published newspaper advertisements containing extracts of unaudited financial results for the quarter and half year ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
2
Neutral
7
Bullish
5
Bearish
28
Neutral
7
Bullish
11
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Arrow Greentech Ltd (ARROWGREEN) is currently trading at 712.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Arrow Greentech Limited develops and manufactures water-soluble films, security products, bio-compostable materials, and patented film-based pharmaceutical delivery systems. Its operations span green packaging, anti-counterfeit technologies, healthcare applications, and intellectual-property monetization, supported by manufacturing and research facilities in India and overseas distribution capabilities. H1 FY27 marked a sharp acceleration: revenue increased 69% year-on-year to ₹1,733 million, while EBITDA nearly doubled to ₹692 million. Profit after tax reached ₹525 million, already exceeding FY26’s full-year PAT, indicating substantial operating leverage and unusually strong first-half execution. The High-Tech Products segment generated ₹1,563 million during H1 FY27, an 88% year-on-year increase, and represented approximately 90% of reported revenue. In contrast, Green Products declined 13%, highlighting that current growth is increasingly concentrated in higher-value technology-led applications rather than the company’s traditional green-products portfolio. Arrow’s competitive moat is built around intellectual property, with 23 patents currently in force globally, more than 10 Indian applications and three foreign applications pending, plus 41 registered trademarks. Four patents were granted during H1 FY27, reinforcing the company’s strategy of commercializing proprietary technologies across packaging, security, healthcare, and related markets. Avery Pharmaceuticals provides a potentially scalable adjacency through patented mouth-dissolving strips, multiple nutraceutical and prescription approvals, WHO-GMP manufacturing, and CDMO capabilities. However, the presentation provides limited revenue disclosure for Avery, so its strategic promise is clearer than its present financial contribution.
Over the past 52 weeks, Arrow Greentech Ltd has traded between a low of ₹342.00 and a high of ₹950.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Arrow Greentech Ltd has a market capitalization of approximately 1,085.80. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Arrow Greentech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.82 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,085.80 Cr, Arrow Greentech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Arrow Greentech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Arrow Greentech Ltd is 14.82. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Arrow Greentech reported revenue from operations of ₹87.8 crore in Q1 FY27. The company said this was 111% higher year-on-year and 110% higher quarter-on-quarter.
Avery Pharmaceuticals says it has more than 54 products approved under FSSAI and more than 10 products under prescription approval. Its presentation separately displays 40 nutraceutical rows and 21 prescription-product rows, which use different classifications.
Arrow Greentech reported H1 FY27 PAT of Rs 52.5 crore. That was 97.1% higher than Rs 26.7 crore in H1 FY26, while PAT margin rose to 29.5% from 25.0%.
Arrow reports 23 granted patents presently in force globally. The company also says it has obtained more than 50 patents over time, which is a cumulative figure rather than the current live count.

Industrial Products
Packaging
1,074 Cr
Low Risk
14.7
31.9
0.5
3.9
950.00
342.00
Sales CAGR
Profit CAGR
ROE
ROCE